Vimta Labs Limited (VIMTALABS) AI Stock Analysis

• Market Cap: ₹18.43B
• Dividend Yield: 0.16%
• Average Volume (3M): 22.50K
• Price to Earnings (P/E): 38.2
• Beta (1Y): 0.95
• Revenue Growth: 17.05%
• EPS Growth: 56.84%
• Country: IN
• Employees: 1,428
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 3.94
• Shares Outstanding: 44,635,190
• 10 Day Avg. Volume: 11,086
• 30 Day Avg. Volume: 22,501
• PEG Ratio: 0.25
• Price to Book (P/B): 2.83
• Price to Sales (P/S): 3.12
• P/FCF Ratio: 68.08
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 67 Neutral
• Price Target: ₹510.00 ▼(-16.29% Downside)
• Action: Upgraded Date: 01/29/26
• Date: Action: Upgraded 01/29/26

The score is driven primarily by strong financial performance (profitability, low leverage, and improving cash flow). This is meaningfully offset by very weak technical momentum and a price trading below all key moving averages, with valuation also not especially compelling given the higher P/E and minimal dividend yield.

Positive Factors

High Profitability Margins

Sustained high gross and operating margins indicate durable pricing power and efficient lab operations across service lines. Margins near these levels support reinvestment in equipment and capabilities, provide a cushion in slower demand periods, and underpin long-term cash generation.

Very Low Financial Leverage

Extremely conservative leverage gives the company flexibility to fund expansion, absorb cyclical downturns, and pursue M&A without stressing interest coverage. A strong equity base reduces refinancing risk and preserves strategic optionality over the medium term.

Improving Cash Generation

Turnaround to positive free cash flow and operating cash conversion above 1.0 signal durable cash generation from core services. Reliable cash inflows can fund capex for lab upgrades, reduce external financing needs, and support steady operations over the next several quarters.

Negative Factors

Modest Free Cash Flow Retention

While FCF turned positive, limited retention suggests much cash is consumed by working capital or non-discretionary uses. This constrains capacity for larger capital projects, shareholder returns, or bolt-on acquisitions without external funding, limiting strategic flexibility.

Moderate Revenue Growth

Single-digit organic growth in a competitive CRO/testing market may limit scale benefits and make it harder to outpace peers. Without acceleration or larger contracts, revenue may not support materially higher investment or faster margin expansion over the medium term.

Very Low Dividend Yield

A negligible dividend reduces appeal to income-focused investors and limits one avenue of shareholder returns. If management prioritizes reinvestment over payouts, investors seeking yield may look elsewhere, potentially narrowing the shareholder base and pressuring stock stability.

Vimta Labs Limited Business Overview & Revenue Model

Company Description

Vimta Labs Limited provides contract research and testing services in India and internationally. It offers laboratory, food and water testing and analysis, preclinical and clinical research, biological molecule structural and functional analysis, environmental assessment, and clinical reference laboratory services. The company serves pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, and various other industries. Vimta Labs Limited was founded in 1984 and is headquartered in Hyderabad, India.

How the Company Makes Money

Vimta Labs generates revenue through multiple streams, primarily by offering comprehensive laboratory testing and analytical services to clients in various industries. Key revenue streams include fees for bioanalytical testing, clinical trials, stability studies, and other specialized testing services. The company also partners with pharmaceutical and biotechnology firms for contract research and development services, which contribute significantly to its earnings. Additionally, Vimta Labs may benefit from government contracts and collaborations with research institutions, enhancing its revenue potential. The consistent demand for quality testing services in health and safety sectors further solidifies its financial performance.

Vimta Labs Limited Financial Statement Overview

Summary

Strong overall fundamentals: solid revenue growth (8.07% from 2024 to 2025), healthy profitability (net margin 19.58%, EBIT margin 25.20%, EBITDA margin 36.69%), and a very conservative balance sheet (debt-to-equity 0.02, equity ratio 81.19%). Cash flow is improving with free cash flow turning positive in 2025, though free cash flow retention remains modest.

Income Statement

Vimta Labs Limited demonstrates strong financial performance with consistent revenue growth, achieving a notable 8.07% increase from 2024 to 2025. The company maintains a robust gross profit margin averaging around 40.76% in 2025, while net profit margin has improved significantly to 19.58% in the same year. The EBIT margin of 25.20% and a strong EBITDA margin of 36.69% indicate efficient operations and cost management.

Balance Sheet

The balance sheet remains solid with a low debt-to-equity ratio of 0.02, reflecting conservative leverage. Return on equity is strong at 17.77%, demonstrating effective use of shareholder capital. The equity ratio stands at an impressive 81.19%, highlighting financial stability and a strong asset base.

Cash Flow

Cash flow analysis reveals positive trends with free cash flow improving from negative in 2024 to positive in 2025. Operating cash flow to net income ratio is healthy at 1.41, indicating strong cash generation relative to net earnings. However, free cash flow to net income ratio remains relatively modest, suggesting room for improvement in cash retention.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	3.84B	3.44B	3.18B	3.15B	2.76B	2.09B
Gross Profit	2.32B	1.33B	2.42B	2.41B	914.08M	1.47B
EBITDA	1.41B	1.26B	902.01M	966.38M	802.74M	533.46M
Net Income	786.29M	673.42M	410.09M	481.72M	413.30M	214.05M
Balance Sheet
Total Assets	5.18B	4.67B	4.00B	3.62B	3.07B	2.74B
Cash, Cash Equivalents and Short-Term Investments	564.64M	327.21M	256.01M	395.73M	112.06M	65.85M
Total Debt	67.97M	85.15M	191.89M	149.88M	193.41M	304.15M
Total Liabilities	1.02B	876.84M	803.54M	805.39M	732.14M	799.75M
Stockholders Equity	4.16B	3.79B	3.20B	2.82B	2.34B	1.94B
Cash Flow
Free Cash Flow	270.48M	157.66M	-156.78M	381.32M	203.45M	40.93M
Operating Cash Flow	748.73M	948.30M	608.92M	879.37M	590.69M	371.82M
Investing Cash Flow	-558.92M	-755.37M	-760.48M	-572.56M	-378.48M	-319.24M
Financing Cash Flow	-66.76M	-166.81M	-19.03M	-109.81M	-166.14M	-45.70M

Vimta Labs Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 609.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIMTALABS, the sentiment is Negative. The current price of 609.25 is above the 20-day moving average (MA) of 452.18, above the 50-day MA of 489.69, and above the 200-day MA of 587.13, indicating a bearish trend. The MACD of -17.57 indicates Positive momentum. The RSI at 32.47 is Neutral, neither overbought nor oversold. The STOCH value of 33.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIMTALABS.

Vimta Labs Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SMSPHARMA	70 Outperform	₹34.24B	29.96	―	0.13%	11.91%	36.92%
VIMTALABS	67 Neutral	₹18.43B	38.21	―	0.16%	17.05%	56.84%
SAKAR	66 Neutral	₹11.31B	22.21	―	―	24.20%	55.01%
KRSNAA	62 Neutral	₹19.42B	38.37	―	0.38%	11.51%	21.56%
SOLARA	54 Neutral	₹20.84B	-36.05	―	―	-4.18%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INDOCO	49 Neutral	₹17.50B	-18.14	―	0.08%	-2.81%	-444.69%